Vera Therapeutics, Inc. (VERA)
Nasdaq: VERA · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2021
Who owns Vera Therapeutics, Inc.
As filed with the SECHolders of 5% or more
6
Avoro Capital Advisors LLC holds 8.9% of Class A Common Stock, $0.001 par value per share, as its SCHEDULE 13G/A filed Feb 14, 2025 says.
Directors and officers
19
report now, of 24 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Avoro Capital Advisors LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Class A Common Stock, $0.001 par value per share
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 30, 2026 · Class A Stock
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed May 15, 2026 · COMMON STOCK · 7.7% in Feb 17, 2026
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
Deep Track Capital, LP
SCHEDULE 13G · filed Mar 11, 2026 · Class A common stock, $0.001 par value per share
Deerfield Mgmt, L.P.
SCHEDULE 13G · filed Jun 11, 2025 · Common Stock
Fmr LLC
SCHEDULE 13G/A · filed Feb 5, 2026 · CLASS A COMMON STOCK · reported falling below 5%
Kynam Capital Management, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Class A common stock, $0.001 par value per share · reported falling below 5%, from 5.37% in Aug 14, 2025
Dr. Maha Katabi ("Katabi")
SCHEDULE 13D/A · filed Mar 5, 2026 · Class A Common Stock, $0.001 par value · reported falling below 5%
Point72 Asset Management, L.P.
SCHEDULE 13G · filed Apr 1, 2026 · Class A Common Stock, par value $0.001 per share · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 5.03% in Jan 30, 2026
What VERA reports owning in othersstakes of 5% or more, and other ties
Vera Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
33sales
1purchases
24sales on a scheduled plan
8people selling
$12.3Msold, in dollars
$200,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 44 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO | 22 | $9.7M | 21 | 0 | $0 |
| Turner William D. | Chief Regulatory Officer | 4 | $1.4M | 3 | 0 | $0 |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 2 | $600,000 | 0 | 0 | $0 |
| Grant Sean | CHIEF FINANCIAL OFFICER | 1 | $200,000 | 0 | 0 | $0 |
| Johnson David Lee | Chief Operating Officer | 1 | $100,000 | 0 | 0 | $0 |
| Brenner Robert | Chief Medical Officer | 1 | $100,000 | 0 | 0 | $0 |
| Skelton Laurence Matthew | Chief Commercial Officer | 1 | $100,000 | 0 | 0 | $0 |
| Carter Jason S | Chief Legal Officer | 1 | $100,000 | 0 | 0 | $0 |
| Enright Patrick G | director | 0 | $0 | 0 | 1 | $200,000 |